Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults

NCT00117923 is registered in ClinicalTrials.gov with Graceway Pharmaceuticals, LLC as lead sponsor.

NCT NCT00117923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00117923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults
Lead sponsor
Graceway Pharmaceuticals, LLC
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2004
Completion date
Not reported
Enrollment
88
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

warts